Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vercirnon

Next Previous
X
Search
Drug Profile

Vercirnon

Alternative Names: CCX-282; CCX-282B; GSK'786; GSK-1605786; GSK-1605786-A; Traficet-EN

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; GlaxoSmithKline
  • Class Anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Crohn's disease; Ulcerative colitis
  • No development reported Coeliac disease

Most Recent Events

  • 20 Oct 2014 Efficacy and adverse events data from the phase III SHIELD-4 trial in Crohn's disease presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG-2014)
  • 19 May 2014 Vercirnon is available for licensing as of 19 May 2014. http://www.chemocentryx.com/
  • 25 Sep 2013 GlaxoSmithKline terminates the global phase III SHIELD programme for Crohn's disease (NCT01316939, NCT01318993 and NCT01536418)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top